SGLT-2 Inhibitors Show Similar Cardiovascular Benefits in T2D
SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.
Related Articles
ESE – World Hormone Day
World Hormone Day brings together the endocrine community to promote endocrine health – Because Hormones Matter. Find out more.
Genetic risk scores for insulin resistance tied to cardiometabolic measures for children
Genetic risk scores for predicting insulin resistance that were developed for adults are also tied to some cardiometabolic metrics in children and adolescents, according to…
Advocacy in Action
The Endocrine Society examines the recent release of the LHHS Appropriations Subcommittee bill as well as the CMS proposed physician fee schedule rule for FY24.
Become an Advocate | ADA
Sign up today! Become an Diabetes advocate, use your voice to help people with diabetes thrive.
Romosozumab Plus Alendronate Improves Lumbar Spine BMD in T2D, Osteoporosis
Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD in postmenopausal women with T2D.
Current Issue Table of Contents: Endocrine Practice
AACE Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
Patient Journey Obesity – Homepage
Obesity is a complex, chronic disease of excessive or abnormally accumulated body fat, resulting in medical problems. Visit the AACE Journey for Patients With Obesity…
Genetic risk scores for insulin resistance tied to cardiometabolic measures for children
Genetic risk scores for predicting insulin resistance that were developed for adults are also tied to some cardiometabolic metrics in children and adolescents, according to…